Navigation Links
Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
Date:5/12/2008

Zicam(R) retail consumer sales increased 25% for the 12 weeks ended March

23, 2008

SCOTTSDALE, Ariz., May 12 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company that develops and markets products that provide consumers with "better ways to get better(R)," today announced its financial results for the fourth quarter and fiscal year ended March 31, 2008.

For the fourth quarter ended March 31, 2008, the Company reported net sales of $33.0 million, a 73% increase above net sales of $19.0 million in the quarter ended March 31, 2007. Net income increased to approximately $5.7 million, or $0.59 per diluted share, compared to net income of approximately $1.7 million, or $0.17 per diluted share, in the prior year's quarter.

For the fiscal year ended March 31, 2008, net sales increased approximately 3%, to $101.0 million, compared to net sales of $97.6 million for the twelve months ended March 31, 2007. Additionally, net income increased approximately 59%, to $10.4 million, or $1.04 per diluted share, compared to net income of approximately $6.5 million, or $0.66 per diluted share, in the twelve months ended March 31, 2007.

Carl Johnson, President and Chief Executive Officer, said, "We are pleased to announce fiscal 2008 net sales exceeded $100 million and our Zicam(R) brand's growth continued to outpace the cough and cold category as a whole. Fiscal 2008 was challenging due to an unusually slow start to the cold and flu season and tightening inventory management practices by certain of our large customers. The cold and flu season did eventually arrive and we realized strong brand momentum during the second half of the cold season. Zi
'/>"/>

SOURCE Matrixx Initiatives, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2008 Financial Results
2. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
4. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
5. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
6. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
7. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
8. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
9. New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits
10. CryoCath Announces Fiscal 2008 Second Quarter Results
11. OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Among early stage breast cancer ... half of one percent will eventually develop leukemia as ... The finding comes from a review of more ... 2007, and it suggests that the risk for developing ... had previously thought. "The frequency of bone marrow ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... screening for disease detection, better surgical techniques available to ... reduce the risk of relapse in patients with both ... to dramatic improvements in breast cancer,s survival rates, according ... at The University of Texas MD Anderson Cancer Center. ...
... HOUSTON - Long associated with a worse outcome, researchers ... have discovered that women treated for breast cancer while ... trend for improved overall survival compared to non-pregnant women ... professor in MD Anderson,s Department of Breast Medical Oncology, ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Sept. ... a progestin hormone may be an effective treatment for ... By delaying a total hysterectomy, which is the ... to remain fertile and possibly to have families, according ...
... Reporter , WEDNESDAY, Sept. 29 (HealthDay News) -- A ... knee pain from osteoarthritis, researchers are reporting. But ... phase 3 trial of the drug after 16 patients ... researcher Dr. Nancy E. Lane, director of the Aging ...
... at the University of California, San Diego shows that California,s ... rates that are nearly 25 percent lower than other states. ... population surveys was reassuring" said John P. Pierce, PhD, Sam ... Family and Preventive Medicine at UCSD School of Medicine and ...
... 28, 2010 Although first responders willingly put themselves in ... not be as willing if the disaster is a potentially ... Columbia University,s Mailman School of Public Health found that more ... they surveyed might be absent from work during a serious ...
Cached Medicine News:Health News:MD Anderson study finds increases in 5-, 10-year survival at every stage of breast cancer 2Health News:MD Anderson study finds increases in 5-, 10-year survival at every stage of breast cancer 3Health News:MD Anderson study finds increases in 5-, 10-year survival at every stage of breast cancer 4Health News:UT MD Anderson study finds women treated for breast cancer while pregnant have improved survival 2Health News: IUD Proposed to Treat Uterine Cancer 2Health News: IUD Proposed to Treat Uterine Cancer 3Health News:Novel Drug Eases Osteoarthritis Knee Pain 2Health News:California's leadership in tobacco control results in lower lung cancer rate 2Health News:Less than half of essential workers willing to report to work during a serious pandemic 2Health News:Less than half of essential workers willing to report to work during a serious pandemic 3
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 ... Pharmaceuticals, Inc. today announced that the Committee for Medicinal ... Agency (EMA) has adopted a positive opinion for the ... of adult men with Peyronie,s disease with a palpable ... at the start of therapy. The use ...
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Company remains committed to speeding innovation ... pipeline boasts 70 potential medicines in clinical development, including 33 in ... ten potential new medicines in Phase III by the end of ... such as neuroscience, diabetes and oncology, as well as new areas ...
... MISSISSAUGA, Ontario, June 30, 2011 Valeant Pharmaceuticals ... VRX) announced today that its subsidiary, Valeant International ... acquire rights to both Elidel (pimecrolimus 1% cream) ... Meda, an international specialty pharmaceutical company (listed on ...
Cached Medicine Technology:Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 2Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 3Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 4Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 5Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 6Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 7Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 8Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 9Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 10Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 11Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 12Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 13Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 14Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 15Lilly Outlines For Investors How Its Innovation-Based Strategy and Robust Pipeline Will Drive Future Growth Following Upcoming Patent Expirations 16Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 2Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™ 3
15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle. Designated most popular model or size....
Grooved roller, on which knife oscillates....
... blade. 17 mm wide blade. ... inches. Note: Has Marcks attachment ... to any thickness up to ... thicker grafts or split graft. ...
5 mm small, sharp, protected blade. Angled at 105 degrees. Flat handle. Designated most popular model or size....
Medicine Products: